Dr. Charles S. Abrams, MD

Dr. Abrams practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Abrams' NPI, 1184668071, was assigned on June 15, 2006. Dr. Abrams graduated from Yale University School of Medicine in 1984. Dr. Abrams holds Pennsylvania license MD034698E.

Dr. Abrams' primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Abrams' primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Abrams is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Abrams to 1 more hospital and 1 medical group, each named with a free account. Dr. Abrams' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abrams practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Abrams' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Abrams is licensed in Pennsylvania.

CMS data shows 152 Medicare services from Dr. Abrams across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $6,416 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Dr. Abrams in 2024. The largest group is 75 to 84, with 47 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abrams' median patient age at 58, with 59% women.

In 2024, Dr. Abrams wrote 120 Medicare Part D claims for 22 patients. 65% of them were for generic drugs. CMS names the drug for 93 of them, across 3 drugs with 11 or more claims each, at $21,658 in total drug cost. In 2023, CMS named 91 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Abrams for performance year 2024, reported as part of a group. Dr. Abrams accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 25 papers to Dr. Abrams, published from 2011 to 2024. 2016 was the busiest year, with 3. The most frequent topics are Blood Platelets, Signal Transduction and Thrombosis. Dr. Abrams has published most often in Blood. Dr. Abrams' most frequent co-authors are Sang Hee Min, MD, Michael Marks, MD and Yelena Z. Ginzburg, MD.

CMS Open Payments shows 1 general payment to Dr. Abrams from 1 drug or device company in 2016. Food and beverage make up the largest share, 100% of the total. Alexion Pharmaceuticals, Inc. paid the most, $18.

Dr. Abrams graduated from Yale University School of Medicine in 1984.